Full-Time
Develops targeted radiation therapies for cancer
No salary listed
Brisbane QLD, Australia
In Person
🩺Medical, Clinical & Veterinary (1) |
---|
Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for urologic cancers like prostate and kidney cancer, neuro-oncology conditions such as glioma, musculoskeletal cancers like sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. The company emphasizes sustainability, patient care, and ethical practices, aiming to create lasting value for patients, shareholders, and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
Telix launches new PET radiochemistry solution.
Telix theranostic programs and satellite symposia on Innovation in PSMA and CAIX imaging featured at SNMMI 2025.
Telix launches new prostate cancer imaging agent, Gozellix, in U.S.
MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Germany for PSMA-PET[3] imaging and will ensure more patients can access this essential diagnostic tool. Illuccix, after radiolabelling with gallium-68, is indicated in Germany for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy
Telix will partner with IRE ELiT S.A. (the radiopharmaceutical subsidiary of IRE Group), a leading provider of radioisotopes and radiopharmaceuticals for nuclear medicine, for the marketing and promotion of Illuccix(R) to healthcare professionals in France.